Related Experiment Video
Updated: Mar 11, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
Published on: June 4, 2012
Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant
Wessam Abdelhady1, Arnold S Bayer1,2,3, Rachelle Gonzales1
1Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Abstract:
We compared the efficacy of telavancin (TLV) and daptomycin (DAP) in an experimental rabbit endocarditis model caused by two clinically derived daptomycin-resistant (DAPr) methicillin-resistant Staphylococcus aureus (MRSA) strains. TLV treatment significantly reduced MRSA densities in all target tissues and increased the percentage of these organs rendered culture negative compared to those with the untreated control or DAP-treated animals. These results demonstrate that TLV has potent in vivo efficacy against DAPr MRSA isolates in this invasive endovascular infection model.
Insights
Telavancin (TLV) effectively treated daptomycin-resistant (DAP r) MRSA endocarditis in rabbits. TLV significantly reduced bacterial loads and increased sterile tissues compared to daptomycin or no treatment.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Daptomycin-resistant (DAP r) methicillin-resistant Staphylococcus aureus (MRSA) poses a significant clinical challenge.
- Endocarditis is a severe invasive infection requiring effective antimicrobial therapy.
Purpose of the Study:
- To compare the in vivo efficacy of telavancin (TLV) and daptomycin (DAP) against DAP r MRSA endocarditis in a rabbit model.
Main Methods:
- An experimental rabbit endocarditis model was established using two clinical DAP r MRSA strains.
- Animals were treated with TLV, DAP, or left untreated.
- Bacterial densities in target tissues were quantified, and the percentage of culture-negative organs was determined.
Main Results:
- TLV treatment significantly reduced MRSA densities in all examined tissues.
- TLV significantly increased the proportion of culture-negative organs compared to untreated and DAP-treated groups.
- Daptomycin treatment showed no significant benefit over the untreated control.
Conclusions:
- Telavancin demonstrates potent in vivo efficacy against daptomycin-resistant MRSA.
- TLV is a promising therapeutic option for invasive infections caused by DAP r MRSA isolates.
Related Concept Videos
Endocarditis I: Introduction
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Antimicrobial Effectiveness
Endocarditis II: Clinical Features of Infective Endocarditis
Antibiotic Selection

